MissionIR Articles
-
VistaGen’s (VSTA) AV-101 Drug Candidate Yields Positive Preclinical Data for Neuropathic Pain Applications
VistaGen Therapeutics, Inc., an emerging biopharmaceutical company, focused on stem cell technologies, to discover, develop and commercialize novel small molecule drugs and protein therapeutics for neurological disorders and diabetes, announced positive results from preclinical studies…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Xanadu Quantum Technologies Limited (NASDAQ, TSX: XNDU) Surges Over 20% On Strong Intraday Trading
- MissionIRNewsBreaks – Future Money Acquisition Corporation (NASDAQ: FMACU) Closes $112 Million Initial Public Offering
- MissionIRNewsBreaks – Linkers Industries Limited (NASDAQ: LNKS) Announces Full Exercise Of Series B Cashless Warrants
- MissionIRNewsBreaks – Perpetuals.com Ltd. (NASDAQ: PDC) Launches On-Premises AI Platform Targeting Fintech and Digital Asset Firms
- MissionIRNewsBreaks – Greenland Energy Company (NASDAQ: GLND) Positioned In Push For Energy Security Amid Global Supply Risks